AHA, others file amicus briefs opposing major drug companies’ 340B rebate models
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources and Services Administration’s decision to reject drug companies’ proposed 340B rebate models in separate lawsuits brought by a number of drug companies to bar the agency from doing so.
The AHA filed the following friend-of-the-court briefs:
- March 6 brief in case brought by Sanofi.
- March 5 brief in case brought by Kalderos.
- March 4 brief in case brought by Eli Lilly, Bristol Meyers Squibb and Novartis.
- Feb. 28 brief in case brought by Johnson & Johnson.
Others joining the AHA in the friend-of-the-court briefs were the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.
Related News Articles
Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…